Rare and Orphan Diseases

1-16 of 43

Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
AudioAbstracts
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
- Marlene Mimi Maeusli, PhD.
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Project Oncology®
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
- Ryan Quigley
- Kathrin M. Bernt, MD
- Rushabh Mehta, BS
- Fatemeh Alikarami
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Project Oncology®
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
- Ryan Quigley
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
- Ryan Quigley
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Project Oncology®
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
- Charles Turck, PharmD, BCPS, BCCCP
- Michael Wang, MD
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
Project Oncology®
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
- Brian P. McDonough, MD, FAAFP
- Doris M. Ponce, MD, MS
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
Project Oncology®
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
- Hallie Blevins, PhD.
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Project Oncology®
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Project Oncology®
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
- Charles Turck, PharmD, BCPS, BCCCP
- Jonathon B. Cohen, MD, MS
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Project Oncology®
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
- Marlene Mimi Maeusli, PhD.
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
Project Oncology®
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
- Charles Turck, PharmD, BCPS, BCCCP
- Sairah Ahmed, MD
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
Project Oncology®
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
- John Cho, MD, PhD, FRCPC
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
Project Oncology®
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
- John Cho, MD, PhD, FRCPC
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Project Oncology®
Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Project Oncology®
Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
Immunotherapy Advances in Squamous Cell Anal Carcinoma: A New Standard of Care
Immunotherapy Advances in Squamous Cell Anal Carcinoma: A New Standard of Care
Project Oncology®
Immunotherapy Advances in Squamous Cell Anal Carcinoma: A New Standard of Care
- Brian P. McDonough, MD, FAAFP
- Midhun Malla, MD